Because tau-PET is clinically expected to show strong diagnostic performance at the dementia stage of AD, it is important to note that in our study, a substantial proportion of Aβ-positive participants with DLB (42.9%) were visual read tau-positive. This evidence concerns the gene MAPT and Alzheimer disease.